Eli Lilly and Company (LILY34) - Total Assets
Based on the latest financial reports, Eli Lilly and Company (LILY34) holds total assets worth R$112.48 Billion BRL (≈ $22.07 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eli Lilly and Company - Total Assets Trend (2014–2025)
This chart illustrates how Eli Lilly and Company's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Eli Lilly and Company - Asset Composition Analysis
Current Asset Composition (December 2025)
Eli Lilly and Company's total assets of R$112.48 Billion consist of 49.5% current assets and 50.5% non-current assets.
| Asset Category | Amount (BRL) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$0.00 | 6.5% |
| Accounts Receivable | R$17.76 Billion | 15.8% |
| Inventory | R$13.74 Billion | 12.2% |
| Property, Plant & Equipment | R$0.00 | 0.0% |
| Intangible Assets | R$6.52 Billion | 5.8% |
| Goodwill | R$5.90 Billion | 5.2% |
Asset Composition Trend (2014–2025)
This chart illustrates how Eli Lilly and Company's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eli Lilly and Company's current assets represent 49.5% of total assets in 2025, an increase from 32.9% in 2014.
- Cash Position: Cash and equivalents constituted 6.5% of total assets in 2025, down from 10.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 11.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 15.8% of total assets.
Eli Lilly and Company Competitors by Total Assets
Key competitors of Eli Lilly and Company based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Roche Holding AG
SW:ROG
|
Switzerland | CHF100.70 Billion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
CSPC Pharmaceutical Group Limited
F:CVG
|
Germany | €46.00 Billion |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357
|
China | CN¥2.89 Billion |
|
Hangzhou Minsheng Healthcare Co Ltd
SHE:301507
|
China | CN¥1.97 Billion |
|
Yung Zip Chemical Ind Co Ltd
TWO:4102
|
Taiwan | NT$927.10 Million |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$1.83 Million |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
Eli Lilly and Company - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.58 | 1.15 | 1.42 |
| Quick Ratio | 1.19 | 0.89 | 1.10 |
| Cash Ratio | 0.00 | 0.12 | 0.00 |
| Working Capital | R$20.40 Billion | R$4.36 Billion | R$4.89 Billion |
Eli Lilly and Company - Advanced Valuation Insights
This section examines the relationship between Eli Lilly and Company's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 37.07 |
| Latest Market Cap to Assets Ratio | 7.59 |
| Asset Growth Rate (YoY) | 42.9% |
| Total Assets | R$112.48 Billion |
| Market Capitalization | $853.51 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Eli Lilly and Company's assets at a significant premium (7.59x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Eli Lilly and Company's assets grew by 42.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eli Lilly and Company (2014–2025)
The table below shows the annual total assets of Eli Lilly and Company from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | R$112.48 Billion ≈ $22.07 Billion |
+42.89% |
| 2024-12-31 | R$78.71 Billion ≈ $15.45 Billion |
+22.98% |
| 2023-12-31 | R$64.01 Billion ≈ $12.56 Billion |
+29.33% |
| 2022-12-31 | R$49.49 Billion ≈ $9.71 Billion |
+1.40% |
| 2021-12-31 | R$48.81 Billion ≈ $9.58 Billion |
+4.66% |
| 2020-12-31 | R$46.63 Billion ≈ $9.15 Billion |
+18.70% |
| 2019-12-31 | R$39.29 Billion ≈ $7.71 Billion |
-10.53% |
| 2018-12-31 | R$43.91 Billion ≈ $8.62 Billion |
-2.38% |
| 2017-12-31 | R$44.98 Billion ≈ $8.83 Billion |
+15.91% |
| 2016-12-31 | R$38.81 Billion ≈ $7.61 Billion |
+9.10% |
| 2015-12-31 | R$35.57 Billion ≈ $6.98 Billion |
-2.03% |
| 2014-12-31 | R$36.31 Billion ≈ $7.12 Billion |
-- |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 7… Read more